OBJECTIVES: To perform a cost-minimization analysis of panitumumab+FOLFOX versus cetuximab+FOLFIRI in the first line treatment of wild-type (WT) RAS metastatic colorectal cancer (mCRC) from the Brazilian Private Healthcare perspective. METHODS: The ASPECCT trial showed that panitumumab and cetuximab had similar efficacy in terms of overall survival (OS) and Progression-Free Survival (PFS). A cost-minimization model was developed based on the assumption of similar treatment efficacy for both regimens. The PFS curve from the PRIME trial was used as a proxy for expected duration of treatment and parametric survival analysis was used to extrapolate beyond the trial period. A mean PFS of 69.27 weeks was estimated for both regimens. The model considered the costs in the private system associated with drug acquisition, treatment administration and incidence of infusion reactions. Direct costs were obtained from literature review and local official reimbursement lists. Scenarios with or without product wastage and dose rounding were assessed. Costs for the year 2016 are expressed in Brazilian currency (BRL) and time horizon corresponds to mean PFS. RESULTS: Panitumumab+FOLFOX is associated with a per-patient cost saving of BRL 187,479 (27.69%) compared to cetuximab+FOLFIRI in the base case scenario where wastage and a dose rounding of 10% have been considered. Acquisition costs were lower for panitumumab vs cetuximab, generating a per-patient saving of BRL 65,351 (22.54%). This represents a cost saving of BRL 18,747,852 per 100 treated patients. Using the savings associated with panitumumab utilization, 38 additional patients could be treated. CONCLUSIONS: Panitumumab+FOLFOX provides similar OS and PFS to a smaller amount of money compared to cetuximab+FOLFIRI in the management of WT RAS mCRC patients. This analysis supports panitumumab instead of cetuximab as the preferred first-line treatment of WT RAS mCRC patients in Brazil. Cost-savings can be used to treat more patients with mCRC given a fixed budget.